Dr Samuel Burch Cheek Jr, MD, MPH | |
427 Broadmoor Dr, Maryville, TN 37803-6583 | |
(865) 380-6516 | |
(865) 977-5449 |
Full Name | Dr Samuel Burch Cheek Jr |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
Location | 427 Broadmoor Dr, Maryville, Tennessee |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1710910211 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Dr Samuel Burch Cheek Jr, MD, MPH 427 Broadmoor Dr, Maryville, TN 37803-6583 Ph: (865) 380-0938 | Dr Samuel Burch Cheek Jr, MD, MPH 427 Broadmoor Dr, Maryville, TN 37803-6583 Ph: (865) 380-6516 |
News Archive
Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.
Allergan plc., a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration for adjunctive treatment of Major Depressive Disorder (MDD).
In a series about the health care systems in five countries, the NewsHour examines the Netherlands and its massive health care overhaul. "When the Netherlands redesigned its national health care system in 2006, there were three main goals: continue universal coverage, unleash competition between private insurers, and keep down costs for the long run.
Researchers from the School of Medicine at The University of Texas Health Science Center at San Antonio have found evidence that directly links disrupted metabolism (energy production in cells) to a common and often fatal type of lymphoma.
› Verified 2 days ago